The anti-cancer activity of 2 himachalene-6-OL extracted from daucus carota SSP. carota. (c2014) by Najm, Paul I.
LEBANESE AMERICAN UNIVERSITY 
 
 
 
 
 
The Anti-Cancer Activity of 2 Himachalene-6-ol Extracted 
from Daucus carota ssp. carota 
 
 
 
By 
 
Paul I. Najm 
 
 
 
 
 
 
 
 
A thesis 
Submitted in partial fulfillment of the requirements 
for the degree of Master of Science in Molecular Biology 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
School of Arts and Sciences 
May 2014 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2014 
Paul Najm 
All Rights Reserved 
! ii!
 
 
 
! iii!
 
 
 
! iv!
 
 
 
 
 
 
 
 
 
 
! v!
ACKNOWLEDGMENTS 
 
This project would not have been possible without the support of many people.  
Many thanks to my advisor, Dr. Mirvat El-Sibai, for her continuous support, 
encouragement, trust, and for helping me get accepted into a PhD program which I could 
never thank her enough for. Also thanks to my committee members, Dr. Costantine 
Daher, and Dr. Mohamad Mroueh, who offered guidance and support. Their acceptance 
for taking part of my thesis committee is highly appreciated.  
I would also like to thank my friends at LAU, who helped me through these years in my 
work and for making these years enjoyable, especially Bechara El Saykali, Saleh El-
Dimassi, Emile Lakkis, Samer Hanna, Anita Nasrallah and Oula Khoury 
And finally, a big thanks goes to my family for their continuous support through all the 
years, and for always offering support and love. 
 
 
 
 
 
 
 
 
! vi!
The Anti-Cancer Activity of 2 Himachalene-6-ol Extracted 
from Daucus carota ssp. carota 
Paul I. Najm 
Abstract 
Daucus carota ssp. carota, known as wild carrot, is a member of the family 
Umbelliferae (Apiacae), and commonly used in the folklore medicine in Lebanon to 
treat several diseases including cancer. Its oil extract and fractions exhibited anti-
oxidant, anti-inflammatory and anti-cancer activities. Daucus carota oil extract was 
chromatographed on silica gel column and produced four fractions: pentane (F1), 50:50 
pentane:diethyl ether (F2), diethyl ether (F3), 93:7 chloroform:methanol (F4) fractions. 
The four fractions were tested against A549, Caco-2, MB-MDA-231, B16F-10, and SF-
268 cancer cells and F2 demonstrated the highest activity. The major compound of F2 
was isolated and identified by GC-MS and NMR spectroscopy as 2-himachalene-6-ol, 
and found to be unique to the Lebanese Daucus carota.  2 himachalene-6-ol showed 
promising anti-proliferative and anti-metastatic abilities against the used cells, with high 
sensitivity against SF-268 cells. Staining with Annexin V and PI, using flow cytometry, 
showed that 2 himachalene-6-ol treatment induced cellular death through necrosis.  
Moreover, time lapse movies and wound healing assays demonstrated that 2 
himachalene-6-ol decreased 2D cellular motility in SF-268 cells in vitro. Adhesion and 
3D invasion assays done also showed that the treatment decreased SF-268 cellular 
adhesion and invasion on collagen in vitro. The significance of the study is that 2 
himachalene-6-ol could be considered towards reaching a potential cancer therapy 
targeting proliferation and apoptosis, as well as cancer motility and metastasis.  
Keywords: Dacaus carota, Cancer, Proliferation, Apoptosis, Metastasis, Motility 
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Chapter One 
LITERATURE REVIEW 
 
1.1. Cancer 
1.1.1. Introduction 
 Cancer is considered among the leading causes of global deaths, as cancer 
accounts for 13% of total deaths worldwide according to the world health organization 
(WHO) (World Health Organization, 2010). Moreover, 1 in 4 deaths in the United States 
are due to cancer (Siegel, Ma, Zou, & Jemal, 2014). In 2012, 14.1 million adults were 
diagnosed with cancer in the world, and 8.2 million deaths were caused by cancer 
worldwide. Moreover, at this expected rate, annual cancer cases are expected to increase 
from 14.1 million in 2012 to 19.3 million cases in 2025 (IARC) (International Agency 
for Research on Cancer, 2013). Statistically, falling right after heart diseases, cancer 
would be considered a disease with high frequency. However, considering the fact that 
cancer could result from a single cell escaping the normal cell cycle, and taking into 
account the high number of cells in an organism, cancer is a very rare disease. As a 
complex disease, the cause of cancer is multifactorial including genetic factors, lifestyle 
factors (diet and tobacco use), physical activity, environmental exposures (chemicals 
and radiations) and certain types of infections. Cancer can occur in different tissues and 
organs in an organism, where different cancers are named according to the type of cell 
from which they arise and their location (American Cancer Society, 2014). Most cancers 
fall into three main groups which are carcinomas, sarcomas, and leukemias or 
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lymphomas, where they occur in the epithelial, mesenchymal and hematopoietic or 
lymphoid cells respectively (Cooper, 2000). 
 Cancer development results from abnormal proliferation of any kind of cell in 
the body. This is achieved when a single cell fails to undergo normal growth cycle and 
more importantly escapes the repair mechanism due to a distortion in its genetic 
material. This results in a tumor formation which could be either benign or malignant. A 
benign tumor is said to be less dangerous as it remains in its original location, neither 
invading neighboring tissue nor spreading into distant sites in the body. A malignant 
tumor, on the other hand, is more severe because of capability of invading surrounding 
normal tissues and can spread to distant body sites through blood or lymphatic 
circulation. Only malignant tumors are referred to as cancer as they acquire the ability to 
invade and metastasize (Cooper, 2000). 
 
1.1.2. Brain and nervous system tumors 
1.1.2.1.Occurrence 
 Brain tumor accounts for 1.4% of all types of cancers, and it is estimated that 
2.4% of all cancer mortalities result from brain and other nervous system tumors 
(Živković, Mihailović, Marković, Berisavac, & Spaić, 2013; Siegel et al., 2014). In 
2014, approximately 23,380 adults in the US will be diagnosed with this primary brain 
and spinal cord cancer, and around 14,320 adults will die from this disease (American 
Cancer Society, 2014).  
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1.1.2.2.Symptoms and risk factors  
 Brain and other central nervous system tumors may cause headaches, nausea, 
vomiting, blurred vision, dizziness, and difficulty in walking or handling objects 
(American Cancer Society, 2014). 
 There are many risk factors leading to disease susceptibility including behavioral 
risk factors such as smoking or alcohol intake, environmental risk factors such as 
exposure to radiations or chemicals, biological risk factors such as aging, and genetic 
risk factors such as family history, and genetic mutations or modification (Reilly, 2009).  
 
1.1.3. Breast tumors  
1.1.3.1.Occurrence 
 Breast cancer is one of the most common cancers in the world, especially in 
women. Breast cancer accounted for around 14.1% of all cancer incidence and 6.8% of 
all cancer deaths in 2012 (Siegel et al., 2014). There are five different types of breast 
cancers all falling under two main groups known as the invasive and the noninvasive 
carcinoma, where the majority are invasive. Women living in the United States have a 
high risk of 12.3%, or a 1-in-8, in their lifetime of being diagnosed with breast cancer. 
Moreover in 2014, 232,670 new cases are estimated of invasive breast cancer and 
40,000 deaths are expected among US women. Additionally, in 2014, about 62,570 new 
diagnostic cases of in situ breast cancer are expected among US women (American 
Cancer Society, 2014). Also, about 2,240 men will be diagnosed with breast cancer and 
410 men will die from the disease (DeSantis, Ma, Bryan, & Jemal, 2013). 
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1.1.3.2.Symptoms and risk factors 
 Breast cancer could be detected before the development of symptoms by a 
screening examination such as a mammography and clinical breast examination (CBE). 
At a later stage, there are certain symptoms that would indicate the occurrence of breast 
cancer such as lump in the breast, swelling and pain, skin irritation, and many others. 
 Breast cancer incidence and death rates generally increases with age, doubling 
until menopause, followed by a dramatic rate decrease. There are several factors that 
increase the risk of breast cancer occurrence such as fat and alcohol intake, smoking, 
weight, radiation, family history, genetic risk factors and others (McPherson, Steel, & 
Dixon, 2000). 
 
1.1.4. Colorectal Tumor 
1.1.4.1.Occurrence  
 Colorectal cancer is the third most common cancer and the fourth most common 
cancer in women in the world right after lung and breast cancers, respectively. 
Moreover, it the third leading cause of death in women and men in the US. An estimate 
of 1.4 million cases were diagnosed in 2012 (IARC) (International Agency for Research 
on Cancer, 2013). In 2014, an estimated 71,830 men and 65,000 women will be 
diagnosed with new colorectal cancer and 26,270 men and 24,040 women will die of the 
disease (Siegel et al., 2014).  
 
1.1.4.2.Symptoms and risk factors 
 Like most cancers, early stage colorectal cancer has no signs of symptoms, thus a 
screening is necessary to detect this cancer at an early level. However, symptoms of this 
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disease appear when there is blood in stool or rectal bleeding, decrease in appetite, pain 
in the lower abdomen, and drastic weight loss (American Cancer Society, 2014).  
  The likelihood of developing colorectal cancer increases with age after the age of 
40, and increases rapidly after the age of 50 (Haggar & Boushey, 2009). Other factors 
that contribute to the increase of this risk include physical inactivity and obesity, alcohol 
intake, smoking, barely eating fruits and vegetables, a family history, and others 
(American Cancer Society, 2014).    
 
 
1.1.5. Lung Tumor 
1.1.5.1.Occurrence 
 Lung cancer causes the most death of all types of cancers in both men and 
women. In 2013, around 228,190 cases of lung cancer were diagnosed accounting for 
14% of all cancer diagnosis. In 2014, around 159,260 deaths will occur, which accounts 
for about 27% of all cancer deaths. In 2014, approximately 224,210 new cases are 
expected. Lung cancers fall under two major categories which are the small-cell lung 
carcinoma (SCLC) (also called oat cell cancer) contributing to 14% of the cases, and 
non-small-cell lung carcinoma (NSCLC) contributing to 84% of the cases. SCLC is 
known to be highly aggressive and approximately 80% of patients have metastatic 
disease at the time of diagnosis. The 5-year survival for non-small cell is around 18%, 
which is higher than that of small cell lung cancer of around 6% (American Cancer 
Society, 2014). 
 
1.1.5.2.Symptoms and risk factors 
 Computed Tomography Screening is an effective technique for screening for 
lung cancer, allowing the detection of an increase in number of small nodules compared 
to other techniques used such as the X-ray scanning (Bach et al., 2007). Symptoms of 
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this disease may include persistent blood cough and chest pain, voice alteration, and 
repeated pneumonia or bronchitis. 
 The highest risk factor contributing to lung cancer is cigarette smoking, 
depending on the quantity and life-time of smoking. Moreover, exposure to unhealthy 
environment such as air pollution and diesel exhaust, in addition to roofing, and 
chimney cleaning, all contribute to an increase risk of developing lung cancer (American 
Cancer Society, 2014). 
  
1.1.6. Skin Tumor 
1.1.6.1.Occurrence 
 The number of skin cancers is difficult to estimate because they are not 
necessarily reported to cancer registries. However in 2006, a report on nonmelanoma 
skin cancer (NMSC) occurrence was done in the US where 3.5 million cases were 
diagnosed and 2.2 million cases were treated. Melanoma, on the other hand, accounts for 
less than 2% of all skin cancer cases, but causes the majority of skin cancer deaths. The 
incidence of melanoma is rare among African-Americans where the risk of disease 
development is 0.1% compared to 2.4% in whites (American Cancer Society, 2014).  
 
1.1.6.2.Symptoms and risk factors 
 Symptoms of melanoma are changes in the skin's shape, size or color and 
pigmentation. Also an appearance of a growth on the skin or a sore that does not heal is 
an indicator for skin cancer. It is important to differentiate between a harmless mole and 
a melanoma using the ABCD rule. According to the ABCD rule it is a melanoma if it 
has the following: A which stands for asymmetry, B for border irregularities, C for color 
(pigmentations), and D for diameter (more than 6mm) (Abbasi et al., 2004).  
 Even thought risk factors vary between different types of skin cancers, there are 
certain factors that contribute to most skin cancer types such as age, gender, radiation, 
!
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exposure to carcinogenic chemicals, family history, moles, high degrees of sun burn, and 
ultraviolet radiation (American Cancer Society, 2014).  
 
1.2 Motility 
1.2.1. Normal Cell Motility 
 Cell migration is vital in multicellular organisms where it is required for many 
biological processes for normal development, such as tissue repair and regeneration, 
immune surveillance, and embryonic morphogenesis (Yamaguchi & Condeelis, 2007). 
For instance, cell motility is crucial as a response to a pathological situation, where 
immune cells invade into infected tissue. Moreover, during wound healing, fibroblasts 
surrounding a wound migrate towards each other (Lambrechts, Van Troy, & Am, 2004). 
On the other hand, cell migration, especially aberrant regulation of cell migration, 
contributes to chronic human diseases including cancer invasion and migration, 
atherosclerosis and chronic inflammatory diseases (Ridley, 2001; Yamaguchi & 
Condeelis, 2007). Thus understanding the mechanisms of cell migration is critical for 
basic cellular biology as well as for preventing the migration of specific cells types that 
could inhibit disease progression (Yamaguchi & Condeelis, 2007).  
 Cell migration is a multistep process where it requires the dynamic and spatially 
regulated changes to the cytoskeleton, cell-substrate adhesions and the extracellular 
matrix. For the cell to migrate, it forms protrusive structures known as filopodia, 
lamellipodia, and podosomes or invadopodia (Yamaguchi & Condeelis, 2007). Usually, 
normal cells move in response to external stimuli in their surrounding environment. 
Chemoattractants trigger cell migration by binding to cell surface receptors and 
stimulating intercellular signaling pathways that regulate the reorganization of the cell's 
actin cytoskeleton. Thus, the cell goes through a transition from a non-polarized to a 
polarized state, and extend their protrusions towards the extracellular triggers they are 
exposed to (Lambrechts et al., 2004; Yamaguchi & Condeelis, 2007). At the leading 
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edge, protrusive structures form and attach through focal contacts on the underlying 
extracellular matrix, and at the rear end protrusive structures detach for the cell to move 
forward. The cell now pulls itself forward as the focal contacts behind the protrusion at 
the leading edge develop into focal adhesions, as observed in figure 1 (Lauffenburger & 
Horwitz, 1996).  
 
 
 
Figure 1: Schematic representation of the different steps of cell migration on 2D 
substrates: 1. Protrusive structures at the leading edge form due to polymerization of 
actin ﬁlaments. 2. New focal adhesions form at the membrane protrusion facilitating the 
binding of transmembrane cell surface receptors to underneath extracellular matrix. 3. 
Contractile forces produced by stress ﬁbers generates a force to move the cell body 
forward. 4. Disassembly of focal adhesions help retract the rear end of the cell (Ladoux 
& Nicolas, 2012).  
!
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1.2.2. Altered cell motility 
 Aberrant regulation of cell migration due to any imbalance or mutation in the 
protein coding genes, contributes to several disorders such as birth defects, immunity 
disorders, and chronic human diseases including cancer invasion and migration, 
atherosclerosis and chronic inflammatory diseases. For example, cellular motility is 
important in embryonic organogenesis, where any mutation affecting the motility of 
these cells would lead to a defect in the development of the organs. Thus, in that case, a 
mutation in vinculin, WAVE1-2, Shroom, or Abl and Arg coding genes cause an 
abnormality of the nervous system, or contribute to more severe cases which results in 
the death of the embryo. In addition, immunity disorders or immunodeficiency might be 
also the result of gene mutations involved within immune cells which disables the 
organism to defend against intrinsic or extrinsic pathogens (Lambrechts et al., 2004). 
 In the case of cancer, numerous crucial proteins have been identified as being 
overexpressed in several types of cancers such as LIM-kinase/cofilin, Wiskott–Aldrich 
syndrome protein (WASP) family proteins/Arp2/3 complex, and cortactin, where they 
contribute to an increase in cell migration and invasion (Yamaguchi & Condeelis, 2007). 
Moreover, other proteins influence migration such as the Rho family proteins, mainly 
RhoA, RhoB, Rac1, Rac2, and Cdc42 (Ridley, 2001). Mutations in Rho-GTPases 
regulating actin binding proteins have shown alterations in motility, where 
downregulation or upregulation of these actin regulatory proteins lead to increased cell 
motility depending on the type of protein or cancer (Lambrechts et al., 2004).  
 
 
1.2.3. Metastasis 
 Metastasis is a journey of cancer cells where they spread from their primary site 
to distant sites in the body leading to the formation of secondary tumors. Secondary 
tumors in general are the major cause of death in cancer patients, and not the primary 
!
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tumors themselves. It is portrayed as a journey in which tumor cells change with time 
from their benign phenotype into an invasive entity, going through several intermediate 
steps (Kumar & Weaver, 2009). Metastasis begins when tumor cells separate from their 
primary site or surrounding cells, and gain a motile and invasive phenotype to 
intravasate towards the blood stream. Subsequently, cancer cells circulate within the 
blood or lymphatic vessels, till they reach their final destination where the living cells 
extravasate and proliferate at their secondary site (Najm & El-Sibai, 2014). Figure 2 
represents the different steps the cell has to undergo in order to metastasize. Protrusive 
structures known as filopodia, lamellipodia and invadopodia/podosomes are crucial for 
the metastatic ability of the cells, in order to migrate and invade through the 
extracellular matrix (Yamaguchi & Condeelis, 2007). Moreover, for the cells to detach 
from their primary tumor and invade, tumor cells not only break their cell-cell 
adhesions, but form cell-matrix adhesive structures in a more transient, migratory and 
adhesive way. After detaching from primary tumor, cells follow a chemoattractive path 
through the extracellular matrix (Yilmaz & Christofori, 2010). In addition, macrophages 
were found to highly contribute in tumor metastasis. Macrophages secrete 
metalloproteinases which helps neoplastic cells in the degradation of the extracellular 
matrix to invade and migrate farther from the primary tumor. In addition, macrophages 
release chemoattractants from the blood vessels to the tumor, which directs tumor cells 
to invade towards the blood vessels, or to what is known as intravasation (Condeelis, 
Wycko, & Segall, 2000). 
 It has been well established that tumor transformation and metastasis are the 
result of both intrinsic and genomic changes within the tumor cells, other than the 
response to extrinsic factors (Kumar & Weaver, 2009). Certain oncogenic events occur 
help contribute to the evolution of tumors to the metastatic state, such as evasion of 
growth suppression or of DNA-damage checkpoints creating genomic instability, 
regulation of specific genes, and the over/under expression of tumor markers (Gupta & 
!
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Massagué, 2006; Kumar & Weaver, 2009). Recent advances in the molecular profiling 
of cancer have revealed genes that are strongly correlated with the likelihood of 
metastatic recurrence, which was done using genomic-level approaches (Weigelt, 
Peterse, Van't Veer, 2005).  
 
 
Figure 2: Schematic representation of the hematogenous metastasis.  
This is an illustration giving insights into the different steps of metastasis. After tumor 
growth in the primary location, this is followed by the detachment of tumor cells from 
the primary tumor by breaking of cell-cell adhesion, invading into the ECM, and 
intravasating towards the blood system. In the blood stream, cancer cells associate with 
platelets and leukocytes to prevent shear forces, circulate in the organism until there is a 
physical arrest via interaction with vascular endothelia, and extravasate followed by 
generation of angiogenesis (Alexander & Bendas, n.d.). 
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1.2.4 Tumor invasion 
 Tumor invasion is a crucial step in the metastatic process of a cell, where it 
occurs twice. Invasion specific genes have been reported in a cluster in pancreatic cancer 
as well as other types of cancers, where several genes showed contribution to the high 
invasion of the cells in different tumor types by being overexpressed by 2-folds or more 
(Ryu et al., 2001). During intravasation, tumor cells detach from their neighboring cells 
at the primary site, acquire their invasive phenotype, and invade through the surrounding 
tissue towards the blood or lymph. Circulating cells reach their destination, adhere again 
to the blood vessel wall and invade through the tissues to a secondary site, or what is 
known as extravasation (Lambrechts et al., 2004).  
 
 
 
Fig.3: The invasion-metastasis cascade: Tumor cells detach from their primary sites of 
growth, followed by local invasion and intravasation towards blood or lymph 
circulation. After surviving in the circulation, survival cells arrest at a distant organ site, 
and extravasate. As a result, metastatic colonization occurs (Faltas, 2012). 
!
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1.3. Cancer treatments 
1.3.1. General 
 There are different approaches for treating cancers depending on the type and 
stage of the cancer. The three most commonly used cancer treatments to date are 
chemotherapy, radiotherapy and surgery.  
 
1.3.1.1. Chemotherapy 
 Chemotherapy has been used to treat cancer in clinics for over than 50 years. 
This method has been successful in treating some tumors, such as testicular cancer and 
certain leukemia, however it did not show the same success with other types of cancers 
such as breast, colon and lung. The ideal situation in chemotherapy is to target tumor 
cells and decrease tumor burden by inducing cytotoxicity without affecting normal cells. 
However, this was not the case when put into test as its effectiveness was less than 
expected due to lack of selectivity, rapid drug metabolism, and drug resistance. 
Multidrug resistance of tumor cells has been a major clinical problem (Johnstone, 
Ruefli, & Lowe, 2002). Due to the lack of selectivity, chemotherapy have shown several 
side effects including diarrhoea, myelosuppression, nausea and vomiting, hepatotoxicity, 
and immunosuppression (Wu, Munro, Guanjian, & Liu, 2005). 
 
1.3.1.2. Radiotherapy 
 Radiotherapy is another commonly used approach to treat cancer, consisting of 
high-radiation exposure of charged particles, X and gamma rays. Radiation therapy 
functions by targeting the DNA of cancer cells, thus kills cells by damaging their DNA 
either directly or by creating free radicals that in turn damage the DNA within the cells. 
Like chemotherapy, radiotherapy lacks selectivity and thus does not target cancer cells 
only, but normal cells as well leading to side effects. In some cases, radiotherapy may be 
used in combination with surgery, chemotherapy or both. Radiation can be either from a 
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machine outside the body, or from radioactive material placed near cancer cells in the 
body. Regarding the type of radiation given to the patient, it depends on several factors 
such as the type of cancer, cancer's location, the size of cancer, patient's general health, 
age, and other factors. Even though radioprotective drugs are used to prevent or 
minimize the damage done on normal tissues, side effects may still occur with 
sometimes a relapse of the tumor (American Cancer Society, 2013).  
 
1.3.1.3. Surgery 
 Surgery is the preferred choice of treatment in case of a local tumor, which could 
be done alone with minimal side effects, or followed by chemotherapy and radiotherapy. 
Surgery could be also performed as a preventive to remove a body tissue that might be 
turning into cancer, even though no signs of cancer at that time exist (American Cancer 
Society, 2014). 
 
 
1.3.2 Phytotherapy 
 Plant and plant extracts have yielded some of the most important drugs for the 
prevention and treatment of several diseases which is why phytotherapy or herbal 
medicine is lately a main focus of research. There are many reasons why traditional 
medicine has been the main focus of scientists in drug development. First, the extracts 
are from nature and safe. Second, they have  reduced and mild toxicity as compared to 
synthetic drugs. Finally, due to more complex reasons related to philosophical and 
religious views (Tavares et al., 2008; Heinrich, Barnes, Gibbons, & Williamson, 2012). 
Moreover, new studies further showed the effectiveness of plant extracts in possessing 
anti-cancer activity, which in turn encouraged more scientists to look deeper into the 
field and try to study the effect of more plants in cancer prevention and reduction 
(Nirmala, Samundeeswari & Sankar, 2011).   
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 Plants secondary metabolites have been found to be an important source for new 
therapeutic agents. Furthermore, several anti-cancer agents have been isolated from 
different plants such as Camptotheca acuminate, Catharanthus roseus, Erythroxylum 
pervillei, Centaurea schischkinii and Taxus brevifolia (Nirmala et al., 2011). Taxol, a 
taxane diterpenoid compound isolated from Taxus brevifolia, has been used in clinical 
practice since 1992 and was proven effective against prostate, breast, ovarian, lung, and 
other types of cancers (Hait, Rubin, Alli, & Goodin, 2007). Other chemical classes of 
anti-cancer compounds derived from plants include vinca alkaloids, epipodophyllotoxin 
lignans, and Camptothecin quinoline alkaloid derivatives (Nirmala et al., 2011).  
 
1.4. Daucus Carota 
1.4.1. Description 
 Daucus carota ssp. carota, belongs to the family Umbelliferae, and known as 
Wild Carrot, Bee's Nest Plant, Bird's Nest Root, Devil's Plague, Bird's Nest Weed, 
Garden Carrot and Queen Anne's lace. It is a biennial herb with spiny fruits which grows 
in dry fields or meadows. Daucus carota is native to Europe and also grows in tropical 
Africa, southwest Asia, Australia, Mediterranean, North and South America. Flower 
develops when the uplifted conical meristem is capable of producing stem elongation 
and an inflorescence. Inflorescence is characterized by a compound umbel, where each 
umbel is made up of several umbellets. Daucus carota are composed of conical shaped 
taproots, tall and branched stems, and alternate leaves (Maxia et al., 2009). 
 
1.4.2. Usage in traditional medicine 
 Daucus carota has been used in treating several cases or diseases. It has been 
used in the Lebanese traditional medicine to treat gastric ulcer, diabetes, muscle pain, 
and to boost immunity and augment liver function. Moreover, it was previously used in 
some villages to treat cancer (Wehbe, Mroueh, & Daher, 2009). Due to its urinary 
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antiseptic and anti-inflammatory effects it was used as a drug to treat cystitis and 
prostatitis in the European folk medicine. In addition to that, it was used as an antifungal 
and antibacterial agent against pathogenic bacteria such as Staphylococcus aureus, 
Escherichia coli and Bacillus cereus (Maxia et al., 2009).  
 It was well established that monoterpenes and sesquiterpenes are present in all 
DC oil extracts, even if they are not completely identical in their composition and come 
from different geographical origins (Maxia et al., 2009). For example, Widdrol, one of 
the compounds found in the oil extract of Daucus carota, has been revealed to inhibit 
proliferation and induce apoptosis in human colon adenocarcinoma cells. Moreover, it 
inhibited HT-29 tumor growth in vivo (Kang et al., 2012). In addition, two 
sesquiterpenes (β-caryophyllene and α-humulene) and two monoterpenes (α-pinene and 
β-pinene) extracted from Z. rhoifolium Lam leaves were revealed to have anti-tumor 
activities in vitro and in vivo (Da Silva, Figueiredo, & Yano, 2007). 
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1.4.3. Work in the lab 
 Previous studies in our lab demonstrated that DC aqueous extract displays 
antiproliferative effects of the human promyelocytic leukemia HL-60 cells (Diab-Assaf, 
El- Sharif, & Mroueh, 2007). Also, the aqueous and methanolic extracts of wild carrot 
umbels showed to have anti-inflammatory effect, and anti-ulcer activities (Wehbe et al., 
2009). In addition, the oil extract of DC produced significant chemo-preventive activity 
against chemically (DMBA-TPA) induced skin carcinogenesis in mice (Zeinab et al., 
2011). Later studies showed that DCOE possesses antioxidant and anticancer activities 
against Caco-2, HT-29, MCF-7 and MB-MDA-231 cancer cell lines. (Shebaby et al., 
2013).   
 Recent work in our lab aimed at fractionating DCOE and evaluating the 
anticancer effects of its fractions on various cell lines in vitro, and mice in vivo. 
Chromatography of DCOE on silica gel column yielded four fractions: 100% pentane 
(F1), 50:50 pentane: diethyl ether (F2), 100% diethyl ether (F3), and 93:7 chloroform: 
methanol (F4). The anti-cancer activities of DCOE fractions were as tested on Caco-2, 
HT-29, MCF-7 and MB-MDA-231 cancer cell lines. Fractions F1 and F2 demonstrated 
the highest activity with IC50 values ranging between 7 and 25 µg/ml. Fraction F2 was 
subjected to further chromatography and its major compound, 2-himachalene-6-ol 
(61.5%), was isolated.  
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1.5. Purpose of the study 
 The objective of the current study is to investigate the anti-cancer effect of 2 
himachalene-6-ol, the major compound isolated from pentane:diethyl ether (50-50) 
fraction F2 of Daucus carota oil extract. Its effect on cell survival was tested against 
A549 lung cancer cells, Caco-2 colon cancer cells, MB-MDA-231 breast cancer cells, 
B16F-10 melanoma cells and SF-268 astrocytoma cells. Further characterization of the 
effect 2 himachalene-6-ol on cellular motility and death was done on astrocytoma SF-
268 cancer cells, being the most sensitive to the treatment. 
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Chapter Two 
 
Materials and Methods 
 
2.1. Cell survival Assay 
 The human breast cancer cell line (MDA-MB231), human astrocytoma cell line 
(SF-268), human colon cancer cell line (Caco-2), human lung adenocarcinoma (A549) 
and human skin melanoma (B16F-10) were maintained in DMEM containing 10% fetal 
bovine serum (FBS) and 100U penicillin/streptomycin at 37°C, 5% CO2 in a humidified 
chamber. Cells were treated with increasing concentrations of 2 himachalene-6-ol for 24 
and 48 hours. Trypan blue (0.4%) was added to the cells and viable and dead cells were 
counted. Cell proliferation was measured by the cell proliferation reagent WST-1 
(Roche Applied Science, Penzberg, Germany), a tetrazolium salt which is cleaved by 
mitochondrial dehydrogenases in metabolically active cells. The intensity of produced 
formazan was measured at 440 nm using a microplate ELISA reader. Cells were plated 
in triplicates and experiments were repeated three times. 
 
2.2. Analysis of Cell Death 
 The type of cell death was determined using fluorescin Isothiocyanate (FITC)-
conjugated Annexin V antibody- (Annexin V-FITC) and PI staining (apoptosis detection 
kit, Abcam, Cambridge, MA). Briefly, 10000 cells/well were plated in 100 µl media in a 
flat-bottom 96-well plate and were incubated. Control cells are left with media alone, 
and other wells were treated with DMSO, 1, 5, 10 and 15µg/ml of DC pure compound 2 
himachalene-6-ol for 24 and 48 hours at 37oC/5% CO2. Cells were then either harvested 
and incubated with  FITC-conjugated annexin V antibody (2.5 mg/ml) and PI (5 mg/ml) 
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in antibody binding buffer for 45 minutes at 37oC  or incubated with a FITC-conjugated 
active caspase inhibitor (ApoStat Apoptosis Detection Kit, R&D Systems, Abingdon, 
England) for 60 minutes then harvested. Cells were then read using a C6 flow cytometer 
(BD Accuri, Ann Arbor, MI). Annexin V/PI data was analyzed on FL1-H versus FL2-H 
scatter plot and caspase activation was detected on FL1-H. Unstained cells were used as 
negative control. Cells were gated on width versus forward scatter. Cells showing  
positive for annexin V staining and negative PI staining are to be considered apoptotic, 
while cells showing positive for both annexin V and PI staining were considered non-
apoptotic/necrotic. 
 
2.3. Western Blot 
 SF-268 cells were treated with IC50 of 4 µg/ml for 24 hrs. The adherent and non-
adherent SF-268 cells were collected on ice, washed twice with PBS, lysed with lysis 
buffer, and centrifuged at 12,000 g for 10 min at 4 ºC. The cell lysate was heated at 100 
ºC for 5 min, and the protein content was determined by the Bio-Rad protein assay (Bio-
Rad, Hercules, CA, USA). The same amount of proteins was loaded to a 10% SDS-
PAGE. Proteins were then transferred to PVDF membrane (Pall Corporation, Ann 
Arbor, USA) and blocked with 5% skim milk for 2 h. The membranes were probed with 
primary antibodies against Actin, Akt, p-Akt, Erk, and p-Erk (Abcam, Cambridge, USA) 
at 4 ºC overnight. Later, the primary antibodies were washed away with TBST for 1 h 
and the membranes were treated with HRP-coupled secondary antibodies (Promega 
Corp., Madison, USA) for 1 h, and washed with TBST afterwards. Finally, Detection of 
each protein was performed using the ECL kit (Abcam plc, 330 Cambridge Science 
Park, Cambridge UK).  
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2.4. Immunostaining  
 Cells were plated on cover slips, and the appropriate treatment was applied. Cells 
were fixed with 4% paraformaldehyde for 10 minutes, and permeabilized with 0.5% 
Triton-X100 for 10 minutes. To decrease background fluorescence, cells were rinsed 
with 0.1M glycine then incubated with 0.1M glycine for 10 minutes. For blocking, cells 
were incubated 4 times with 1% BSA, 1% FBS in PBS for 5 minutes. Samples were 
stained with rhodamine phalloidin for 30 minutes. Fluorescent images of the stained 
cells stained were taken using a 60X objective on an upright fluorescent microscope. 
 
 
2.5. Wound healing assay  
 Cells were grown to confluence on culture plates, appropriate treatment for 24 
hours were applied, and a wound was made in the monolayer with a sterile pipette tip. 
After wounding, the cells were washed to remove debris and new medium was added. 
Phase-contrast images of the wounded area were taken at 0 and at 24 hours after 
wounding. Wound widths were measured at 12 different points for each wound, and the 
average rate of wound closure was calculated in µm/hr. 
 
2.6. Motility assay  
 For motility analysis, images of cells moving randomly in serum were collected 
every 60 seconds for 2 hours using a 20X objective. During imaging, the temperature 
was controlled using a Nikon heating stage which was set at 37°C. The medium was 
buffered using HEPES and overlayed with mineral oil. The speed of cell movement was 
quantified using the ROI tracker plugin in the ImageJ software, which was used to 
calculate the total distance travelled by individual cells. The speed is then calculated by 
dividing this distance by the time (120 minutes) and reported in µm/min. The speed of at 
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least 5 cells for each condition was calculated. The net distance travelled by the cell was 
calculated by measuring the distance travelled between the first and the last frames. 
 
2.7. Adhesion Assay 
 96-well plates were coated with collagen using Collagen Solution, Type I from 
rat tail (Sigma) overnight at 37°C then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37°C in a CO2 
incubator for 1 hour. This was followed by washing the plates and chilling them on ice. 
Meanwhile, the previously 24 hours treated cells were trypsinized and counted to 4x105 
cell/ml. The cells were added in each well and incubated at 37°C in a CO2 incubator for 
30 minutes. The plates were then shaken and washed 3 times. Cells were then fixed with 
4% paraformaldehyde at room temperature for 10 minutes, washed, and stained with 
crystal violet (5mg/ml in 2% ethanol) for 10 minutes. Following the staining with crystal 
violet, the plates were washed extensively with water, and left to dry completely. Crystal 
violet was solubilised by incubating the cells with 2% SDS for 30 minutes. The 
absorption of the plates was read at 550 µm using an ELISA plate reader. 
 
2.8. Invasion assay 
 Invasion assay was performed 24 hrs following treatment period using the 
collagen-based invasion assay (Millipore) according to manufacturer’s instructions. 
Briefly, 24 hrs prior to assay, cells were starved with serum free medium. Cells were 
harvested, centrifuged and then resuspended in quenching medium (without serum). 
Cells were then brought to a concentration of 1x106 cells/ml. In the meantime, inserts 
were pre-warmed with 300 µl of serum free medium for 30min at room temperature. 
After rehydration, 250 µl of media was removed from inserts and 250 µl of cell 
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suspension was added. Inserts were then placed in a 24-well plate, and 500 µl of 
complete media (with 10% serum) was added to the lower wells. Plates were incubated 
for 24 hrs at 37oC in a CO2 incubator. Following incubation period, inserts were stained 
for 20min at room temperature with 400 µl of cell stain provided with the kit. Stain was 
then extracted with extraction buffer (also provided). 100 µl of extracted stain was then 
transferred to a 96-well plate suitable for colorimetric measurement using a plate reader. 
Optical Density was then measured at 560 µm. 
 
2.9. Statistical Analysis 
 
 Results were expressed as mean ± SEM of three experiments. Comparison of 
each group with the control was made by independent t-test. A P-value less than 0.05 
was considered to be significant.  
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Chapter Three 
 
Results 
 
3.3. The effect of 2 himachalene-6-ol on cell survival in vitro 
 
3.3.1. Effect of 2 himachalene-6-ol on A549 cell survival 
 The effect of 2 himachalene-6-ol was tested on A549 lung cell line over 24 and 
48 hours. The cells were treated with DMSO and different concentrations of the drug. 
Treatment showed a dose-dependent effect with maximum inhibition of proliferation at 
concentration of 25 µg/ml. The IC50 value at both 24 hours and 48 hours was 5 µg/ml., 
where no significant difference was observed. 
 
Figure 4: Effect of 2 himachalene-6-ol on A549 cell survival. A549 human cancer 
cells were treated with DMSO and different concentrations of the 2 himachalene-6-ol for 
24 and 48 hours. Bars denote mean ± SEM (n=3). * p<0.05 compared with DMSO.  
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3.3.2. Effect of 2 himachalene-6-ol on Caco-2 cell survival 
 The effect of 2 himachalene-6-ol was tested on Caco-2 colon cell line over 24 
and 48 hours. The cells were treated with DMSO and different concentrations of the 
drug. The effect of the treatment appeared to be dose-dependent with maximum 
inhibition of proliferation at concentration of 25 µg/ml. The IC50 value at both 24 hours 
and 48 hours approximately 8 µg/ml. There was no significant difference observed 
between treatment for 24hours and 48hours. 
 
Figure 5: Effect of 2 himachalene-6-ol on Caco-2 cell survival. Caco-2 colon human 
cancer cells were treated with DMSO and different concentrations of the 2 himachalene-
6-ol for 24 and 48 hours. Bars denote mean ± SEM (n=3). * p<0.05 compared with 
DMSO. 
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3.3.3. Effect of 2 himachalene-6-ol on B16F-10 cell survival 
 The effect of 2 himachalene-6-ol was tested on B16F-10 melanoma cell line over 
24 and 48 hours. Cells were treated with DMSO and different increasing concentrations 
of the drug. The effect of the treatment appeared to be dose-dependent with a high 
inhibition of proliferation at concentration of 25 µg/ml. The IC50 value at both 24 hours 
and 48 hours approximately 13 µg/ml. There was no significant difference observed 
between treatment for 24hours and 48hours. 
 
Figure 6: Effect of 2 himachalene-6-ol on B16F-10 cell survival. B16F-10 melanoma 
human cancer cells were treated with DMSO and different concentrations of 2 
himachalene-6-ol for 24 and 48 hours. Bars denote mean ± SEM (n=3). * p<0.05 
compared with DMSO. 
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3.3.4. Effect of 2 himachalene-6-ol on MB-MDA-231 cell survival 
 The effect of 2 himachalene-6-ol was tested on MB-MDA-231 breast cancer cell 
line over 24 and 48 hours. Cells were treated with DMSO and different increasing 
concentrations of the drug. The effect of the treatment appeared to be dose-dependent 
with a high inhibition of proliferation at concentration of 25 µg/ml. The IC50 value at 
both 24 hours and 48 hours was approximately 6 µg/ml. There was no significant 
difference observed between treatment for 24hours and 48hours. 
 
Figure 7: Effect of 2 himachalene-6-ol on MB-MDA-231 proliferation. MB-MDA-
231 breast human cancer cells were treated with DMSO and different concentrations of 
2 himachalene-6-ol for 24 and 48 hours. Bars denote mean ± SEM (n=3). * p<0.05 
compared with DMSO. 
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3.3.5. Effect of 2 himachalene-6-ol on SF-268 cell survival 
 The effect of 2 himachalene-6-ol was tested on SF-268 brain cancer cell line 
over 24 and 48 hours. Cells were treated with DMSO and different increasing 
concentrations of the drug. The effect of the treatment appeared to be dose-dependent 
with a high inhibition of proliferation at concentration of 25 µg/ml. The IC50 value at 
both 24 hours and 48 hours approximately 4 µg/ml. There was no significant difference 
observed between treatment for 24hours and 48hours. 
 
Figure 8: Effect of 2 himachalene-6-ol on SF-268 cell survival. SF-268 human cancer 
cells were treated with DMSO and different concentrations of 2 himachalene-6-ol for 24 
and 48 hours. Bars denote mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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3.4. The effect of 2 himachalene-6-ol on cell death 
 To determine whether the treatment induces cell death by apoptosis or necrosis, 
cells were stained with annexin and PI. After the cells were plated, control cells were 
left with media alone, and the rest were treated with DMSO, and different 2 
himachalene-6-ol concentrations of 1, 5, 10, 15 µg/ml.  Cells that were positive for 
annexin V staining and negative PI staining would be considered apoptotic, while cells 
showing positive for both annexin V and PI staining would be considered non-
apoptotic/necrotic. The results below showed positive staining for PI and annexin V  
thus the cells were necrotic or in other words the treatment induces cell death through 
necrosis. 
 
Figure 9: The effect of 2 himachalene-6-ol on cell death. Control cells were left with 
media alone. DMSO treated cells were only treated with DMSO. The cells in other 
plates were treated with different 2 himachalene-6-ol concentrations of 1, 5, 10 and 15 
µg/ml. Control and DMSO treated cells showed a healthy population with negative 
staining for both PI and annexin V. However with increasing concentrations of 2 
himachalene-6-ol cells were stained more and more with annexin V as well as PI, thus 
showing necrosis. 
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3.5. The effect of 2 himachalene-6-ol on molecular regulators of cellular 
proliferation 
 
3.5.1. Effect of 2 himachalene-6-ol on ERK/p-ERK expression on SF-268 cell line 
 The level of phosphorylation of ERK in treated and control cells was tested 
through Western blot. The control and treated cells were lysed, run on a gel, and blotted 
on a nitrocellulose membrane. Anti-ERK and anti-pERK antibodies were used to detect 
the levels of expression. A decrease in p-ERK expression was noticed in treated cells. 
    
 
 Figure 10: ERK/p-ERK expression in control and treated cells. Cells were 
treated with DMSO as a control and with 4 µg/ml of DC 2 himachalene-6-ol. A) Gel 
bands showing a decrease in expression of p-ERK in treated compared to control, 
normalized against ERK. B) Bands were quantified using imageJ and normalized to 
ERK as the control. Bars denote mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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3.5.2. Effect of 2 himachalene-6-ol on AKT/p-AKT expression on SF-268 cell line 
 The level of phosphorylation of AKT in treated and control cells was tested 
through Western blot. The control and treated cells were lysed, run on a gel, and blotted 
on a nitrocellulose membrane. Anti-AKT and anti-pAKT antibodies were used to detect 
the levels of expression. A decrease in p-AKT expression was noticed in treated cells. 
 
Figure 11: AKT/p-AKT expression in control and treated cells. Cells were treated 
with DMSO as a control and with 4 µg/ml of DC 2 himachalene-6-ol. A) Gel bands 
showing a decrease in expression of p-AKT in treated compared to control, normalized 
against AKT. B) Bands were quantified using imageJ and normalized to AKT as the 
control. Bars denote mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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3.6. Effect of 2 himachalene-6-ol on stress fiber formation in SF-268 
 
 Since it was expected to decrease cells motility by possibly decreasing actin turn 
over and formation of actin stress fibers, it was interesting to look at the effect using 
immunostaining techniques. After the cells were plated and treated, they were fixed and 
stained using Rhodamine phalloidin conjugated to a secondary antibody. The results 
were consistent and showed a decrease in stress fibers (Figure 12). 
 
 
   DMSO     4µg/ml 
         
 
Figure 12: The effect of 2 himachalene-6-ol on actin filaments by Rhodamine 
phalloidin staining. A decrease in actin filaments was observed on the right panel 
(4µg/ml) relative to the left (DMSO). 
 
 
 
 
 
 
 
!
!
33!
3.7. Effect of 2 himachalene-6-ol on SF-268 cell motility  
 
3.7.1. The effect of wound healing ability of SF-268 
 To test the effect of 2 himachalene-6-ol on SF-268 motility we started by doing 
the wound healing assay. The cells were plated, treated after 24 hrs and then a wound 
was performed of which cells were fed with serum free media. Pictures were taken at 0 
hrs and 24 hrs later. The results assessed using the image J software showed a decrease 
in wound closure in around 59%. The control cells treated only with DMSO had an 
average rate of 7.06 µm/hr, whereas cells treated with 4 µg/ml of the 2 himachalene-6-ol 
have closure rate of 2.93 µm/hr (Figure 13).  
 
 
Figure 13: 2 himachalene-6-ol inhibits the wound closure ability of SF-268 cell line. 
A) SF-268 cells were grown in a monolayer then treated with 2 himachalene-6-ol for 24 
hrs. Post treatment, cells were wounded imaged at 0hrs and left to recover the wound for 
24hrs where the wounds were imaged again at the same frame. B) Quantification for A. 
Wound widths were measured at 12 different points for each wound and the average rate 
of wound closure for the DMSO and treated cells was calculated in µm/hr. The decrease 
was significant with a p value less than 0.05. Bars denote mean ± SEM (n=3). 
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3.7.2. The effect of 2 himachalene-6-ol on SF-268 cell line 2D motility  
 Cells were plated and then treated with either DMSO control or 2 himachalene-
6-ol 4µg/ml in DMSO. Images were taken every 60 seconds for 120 frames. The average 
cell speed, measured using the image J software and showed a 60% decrease in cellular 
motility.  
 
 
 
Figure 14: 2 himachalene-6-ol inhibits 2D cell motility. Quantitation was done using 
image J, and the decrease was significant with a p-value less than 0.05. Bars denote 
mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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3.8. Effect of 2 himachalene-6-ol on SF-268 cell adhesion to collagen 
 Since treatment with 2 himachalene-6-ol caused a decrease in cellular motility, it 
was interesting to look for its effect on adhesion which plays a crucial role in cellular 
motility. The results were consistent with the motility data as 2 himachalene-6-ol 
increased cellular adhesion. Data showed almost 2 fold increase in adhesion compared 
to control group (Figure 15). 
 
 
 
Figure 15: The Effect of 2 himachalene-6-ol on SF-268 cellular adhesion. After 
plating treated cells on collagen, crystal violet was solubilised. A) Pictures were taken of 
the stained cells on collagen matrix and B) the absorption of the plates was read at 560 
nm using an ELISA plate reader. Data is measured in arbitrary units and normalised to 
the control. Bars denote mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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3.9. Effect of 2 himachalene-6-ol on 3D invasion of cells 
 After obtaining a potent effect on the inhibition of 2D motility, it was appealing to 
investigate the effect of 2 himachalene-6-ol on the 3D motility by doing the invasion assay. 
Cells are plated in a chamber coated with collagen and serum free media and allowed to 
migrate to the other chamber containing FBS, where FBS was used as a chemoattractant in 
this assay. Results show that there was nearly a quarter-fold decrease in cell invasion as 
compared to the control cells (Figure 16). 
 
 
Figure 16: Treatment with 2 himachalene-6-ol inhibits invasion of SF-268 cancer 
cells. A) Invaded cells to the bottom side of the membrane were stained according to 
assay instruction. Control cells treated with DMSO and treated cells were allowed to 
invade towards 10% FBS for 24 hrs. B) Cell stain was extracted and colorimetric 
measurements were taken at 560 µm. Data is measured in arbitrary units. Bars denote 
mean ± SEM (n=3). * p<0.05 compared with DMSO. 
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Chapter Four 
Discussion 
 
 Natural products of plant origin have been a good source of many drugs for the 
treatment of different diseases such as cancer. Many phytochemicals were found to 
possess a wide range of effects on different types of cancer through inhibition of 
proliferation and inducing apoptosis (Nirmala et al., 2011). Other mechanisms of anti-
cancer phytochemicals include induction of cell cycle arrest, inhibit tumor angiogenesis, 
cancer invasion and malignancy (Mehta, Murillo, Naithani, & Peng, 2010; Limin, Ka-
Lung, Tin Oo, Chi, & Ah-Ng, 2010).  
 2 himachalene-6-ol, isolated from pentane:diethyl ether (50-50) fraction F2 of 
DCOE, showed promising results in decreasing cell survival when tested against Caco-
2, MB-MDA-231, A549, B16F-10, and SF-268 cancer cells. It showed an IC50 at 
concentrations ranging 4µg/ml and 14µg/ml, with no significant difference between 24 
and 48hours post treatment. 2 himachalene-6-ol demonstrated similar results in inducing 
cellular death and decreasing cellular growth as Widdrol, an isomer extracted from 
Juniperus chinensis (figure 17) (Ali et al., 1996). Widdrol has been previously studied to 
inhibit the in vitro growth and induce apoptosis in human colon adenocarcinoma cells 
(Kwon et al., 2010; Kang et al., 2012). 
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Figure 17: Chemical structures of Widdrol and 2 himachalene-6-ol (Kang et al., 
2012) 
 
 
  
 SF-268 astrocytoma cells showed the highest sensitivity to 2 himachalene-6-ol 
treatment, with a 4µg/ml IC50 value, thus further characterization of its effect was 
carried on this cell line. Cell death analysis was carried out to determine whether the 2 
himachalene-6-ol induces cell death through apoptosis or necrosis. Flow cytometry 
results showed that cellular death induced by 2 himachalene-6-ol is mediated through 
necrosis, as cells were stained positive by both fluorescent annexin V and PI. To 
elucidate the mechanisms of the anti-proliferative activity of 2 himachalene-6-ol, two 
main pathways were targeted which are the PI3 kinase pathway and the MAP kinase 
pathway. The MAP kinase pathway in known to control crucial cellular processes such 
as cell growth, proliferation, differentiation, migration and apoptosis (figure 18) 
(Dhillon et al., 2007). The level of phosphorylation of ERK, which reflects activation, 
between control and treated groups was investigated. Treatment with 2 himachalene-6-ol 
caused a decrease in phosphorylation of ERK thus inhibiting its activation. This was 
expected as treatment inhibited proliferation and induced apoptosis. 
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Figure 18: Schematic overview of MAPK pathways (Dhillon et al., 2007). 
 
 
 The next pathway targeted was the phosphoinositide 3-kinase (PI3K) pathway 
which has been established to play a key role in the signal transduction system that links 
oncogenes to many essential cellular functions such as cell growth, proliferation, 
differentiation, survival, motility and others (figure 19) (Lawlor & Alessi, 2001). 
Moreover, this pathway is considered one of the most commonly activated signaling 
pathway in human cancers (Liu et al., 2009). Thus, looking at the level of AKT 
phosphorylation, which reflects activation, between control and treated groups, treated 
cells exhibited a decrease in p-AKT levels. The effect of 2 himachalene-6-ol on PI3 
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kinase pathway was less pronounced than that on MAP kinase, which might suggest 
selectivity.  
 
 
Figure 19: Schematic representation showing the critical role of PI3 kinase 
pathway in cellular functions (Tzenaki & Papakonstanti, 2013).  
 
  
 
 The effect of 2 himachalene-6-ol on cellular motility was evaluated, and results 
showed that it decreased 2D and 3D cellular motility in vitro. Knowing that astrocytoma 
SF-268 cancer cells are highly motile and invasive, two different motility assays were 
performed to determine the effect of 2 himachalene-6-ol on its 2D motility. The two 
assays done were the wound healing and the time lapse experiments. 2 himachalene-6-ol 
showed pronounced effect on the motility of SF-268. The rate of wound closure in the 
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wound healing experiments decreased, as well as the speed of cell motility shown by 
time lapse movies. A decrease cellular motility upon treatment was confirmed by 
quantification using imageJ. 
   Cellular adhesion is crucial for cell motility and invasion. Cells having an 
increase in adhesion will not be able to detach and move forward, as well as cells having 
low adhesion will not be able to pull themselves forward (figure 1). Therefore,  adhesion 
is a cycling process where cells need to lose their adhesion in order to move forward. 2 
himachalene-6-ol treated cells showed an increase in adhesion, which partially explains 
the reduced cell motility.  
 3D invasion assay was carried out as to assess the invasion and metastatic 
capability of treated cells with 2 himachalene-6-ol. This is crucial as invasion is  a very 
important step during metastasis where the cells should dislocate from their original 
location and invade to or from the circulatory system (figure 2). Upon treatment with 2 
himachalene-6-ol, a decrease in invasion was observed which shows that the treatment 
might be promising in inhibiting metastasis in vivo in future work.  
 The final step was to investigate the effect of 2 himachalene-6-ol on the actin 
cytoskeleton of the SF-268 cells. Actin bundles are composed of individual actin 
filaments that are arranged in parallel arrays, tightly packed, and crosslinked by proteins 
that are crutial for cellular movement such as fascin, fimbrin and scruin. Actin filaments 
connect to distal adhesion points are the front end, allow tension to propagate towards 
the new focal adhesions, thus enabling the cell to move forward. Thus, actin filaments, 
with the help of myosin, are mainly responsible for cellular motility (Ananthakrishnan & 
Ehrlicher, 2007). The effect of 2 himachalene-6-ol on actin filaments was tested by an 
immunostaining assay, using rhodamine phalloidin which binds to F-actin. A decrease in 
formation of actin filaments was observed in treated cells compared to the control group, 
which explains the decreased in cellular motility. 
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Chapter Five 
Conclusion 
 
 The results obtained in our lab looked promising as the treatment with DC major 
compound 2 himachalene-6-ol caused inhibition of cellular proliferation as well as 
motility and metastasis. Continuous studies are being carried out to reveal the exact 
molecular pathways involved in inhibiting proliferation and motility, as well as look at 
its effect on focal complexes and adhesion. In vivo experiments are undergoing to 
confirm the in vitro results obtained, and preliminary data show that 2 himachalene-6-ol 
has promising effect on inhibiting metastasis. Daucus carota oil extract, fractions and 2 
himachalene-6-ol till now has satisfied the guidelines to be a potential anti-cancer 
therapy. However, more studies are needed to be done in vivo to be convinced. The 
significance of this study is towards reaching a potential anti-cancer drug from wild 
carrot, specifically targeting cancer cellular proliferation as well as motility and 
metastasis. 
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